CTOs on the Move

Synspira

www.synspira.com

 
Synspira Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF) and other rare diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.synspira.com
  • 10 Speen St, 302
    Framingham, MA USA 01701
  • Phone: 617.466.3111

Executives

Name Title Contact Details

Funding

Synspira raised $14M on 10/20/2020

Similar Companies

Ideaya Biosciences

IDEAYA Biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting DNA damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. Founded in 2015, IDEAYA`s investors include 5AM Ventures (5AM), Canaan Partners (Canaan), Celgene, WuXi Healthcare Ventures (WuXi), Novartis Institute of Biomedical Research, and Alexandria Real Estate. The Company has assembled a world-class drug discovery team and Scientific Advisory Board (SAB) that is represented by a Nobel Laureate and three Members of the National Academy of Sciences. IDEAYA is located in South San Francisco and La Jolla, California.

Advanced MRI Consulting

Advanced MRI Consulting is a Evergreen Park, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

POINTONE Systems

POINTONE Systems is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T-knife

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company`s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.

MYM Nutraceuticals

MYM Nutraceuticals Inc. (CSC:MYM) (OTC:MYMMF) (FRA:OMY) is an emerging bio-pharmaceutical company and distributor of medical marijuana products that has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. MYM Nutraceuticals has an extensive list of industry assets that make it well prepared for commercial distribution of medical marijuana, including a growing facility property, exclusive access to patients and many years of industry expertise on the company`s board of directors and staff.